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ABSTRACT  
 
Failure to predict drug-induced toxicity reactions is a major problem contributing to a 
high attrition rate and tremendous cost in drug development. Drug screening in X. 
laevis embryos is high-throughput relative to screening in rodents, potentially making 
them an ideal model organism for this use. Xenopus embryos have been used as a 
toxicity model in the frog teratogenesis assay-Xenopus (FETAX assay) for the early 
stages of drug safety evaluation. We have previously developed compound-screening 
methods using Xenopus embryos and believe they could be used for in vitro drug-
induced toxicity safety assessment prior to expensive preclinical trials in mammals. 
Specifically, Xenopus embryos could help predict drug-induced hepatotoxicity and 
consequently aid lead candidate prioritization. Here we present methods, which we 
have modified for use on Xenopus embryos, to help measure the potential for a drug 
to induce liver toxicity. One such method is the release of the liver-specific micro-RNA 
(miRNA), miR-122, from the liver into the vasculature as a result of hepatocellular 
damage, which could be due to drug-induced acute liver injury.  Paracetamol, a known 
hepatotoxin at high doses, was a positive control. We have previously shown that 
some of the phenotypes of mammalian paracetamol overdose are reflected in 
Xenopus embryos. Consequently, we have also included a method that measures the 
concentration of free glutathione (GSH), which is an indicator of paracetamol-induced 
liver injury. These methods can be used as part of a panel of protocols to help predict 
the hepatoxicity of a drug at an early stage in drug development. 
 
MATERIALS 
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It is essential that you consult the appropriate Material Safety Data Sheets and your 
institution’s Environmental Health and Safety Office for proper handling of equipment 
and hazardous materials used in this protocol. 
 
Reagents 
Agarose gel (2% [w/v]; Sigma-Aldrich 
Bradford assay kit (BIO-RAD) 
GSH (0.1 mM; Sigma) 
GSH assay reagent <R> 
GSH buffer <R> 
GSH reductase (13 U/mL in GSH buffer; Sigma Aldrich)  
HCl (10 mM) 
Liquid nitrogen (optional; see Step 6) 
MEM salts (10X; pH 7.4) <R> 
MEMFA fixative for Xenopus <R> 
miRCURYTM LNA PCR Primer mix for Xenopus miR-122 (Exiqon) 
miRCURYTM LNA PCR Primer mix for Xenopus miR-103 (Exiqon)  
MMR (10X; pH 7.5) <R> 
Paracetamol and/or drug to be texted (2X final desired concentration) 
PBS (P) <R>  
PBS; 0.1 % tween-20 (PBST) 
RNA isolation and cDNA synthesis kit   
RNase free water 
5-sulfosalycylic acid hydrate (SSA; 6.5 % (w/v)) 
SYBR® Green PCR Master Mix (Applied Biosystems)  
Tricaine (0.5 mg/mL in 0.1X MMR) 
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X. laevis embryos (Nieuwkoop and Faber (NF) stage 1; Nieuwkoop and Faber, 1994) 
 
Equipment 
Applied Biosystems 7500 Fast Real-Time PCR system  
Breathe-EazyR Sealing membranes (Sigma, UK) 
Culture incubator (set to temperature indicated below) 
Culture plate (96 or 24-well; non-cell culture grade; Fisher Scientific) 
Dumont #5 forceps (stainless steel; Sigma-Aldrich) 
Ultrafine for careful manipulation of embryos 
Eppendorf pestle 
Freezer (-20 oC) 
Glass vials with screw caps (3.5 ml; SGL) 
Light microscope with charge coupled-device (CCD) digital camera for whole-mount 
imaging of embryos 
Long-handled scalpel (10A blades) 
MicroAmp optical 96 well plate (Applied Biosystems) 
Microcentrifuge 
Microcentrifuge tubes 
Parafilm MTM wrapping film (Fisher Scientific) 
Pasteur pipette 
To use plastic Pasteur pipettes, cut the end off with scissors. For glass pipettes, mark 
the end with a diamond pen, break off cleanly and fire the end briefly to melt any sharp 
edges. 
Petri dish (3 cm2 and 10 cm2; Fisher Scientific) 
Razor 
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Spectrophotometer such as GloMaxR Explorer System (Promega) 
Stereomicroscope with two-armed fiber optic illuminator to allow easy adjustment of 
the angle of illumination  
Vortex 
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METHODS 
Before examining hepatoxicity, the overall toxicity of a small molecule or compound 
needs to be determined, including the maximum dose that embryos can be exposed 
to before they all consistently die (Saide et al., 2019). This will determine a range of 
concentrations to use to test for hepatoxicity below the maximum dose.  
 
Assays for liver toxicity 
These protocols were developed using paracetamol, which is associated with acute 
liver injury in humans after overdose administration, as a model drug. This drug can 
be used as a positive control in these methods and for comparisons with 
drugs/compounds being tested. 
1. Harvest NF stage 1 X. laevis embryos as in Al-Yousuf et al., 2017 and incubate 
in 0.1X MMR in petri dishes between 13–23oC until stage 38. Regularly observe 
the embryos (at least twice daily or more at early stages) to remove any dead 
embryos and ensure the correct NF stage has been reached. It should take 
roughly 4 days to reach stage 38.  
2. In a 96-well plate, add 125 L of a 2X final concentration of paracetamol or the 
drug to be tested dissolved in 0.1X MMR. For the negative control add 125 L 
0.1X MMR to the well. Add 1 stage 38 embryo (Nieuwkoop and Faber; 1994) 
in 125 L 0.1X MMR to each well using a cutoff pipette tip. The final volume of 
each well is 250 L. 
 
When testing paracetamol, a range of 0 – 5 mM generated a paracetamol-
induced liver injury phenotype that was similar to that observed in other animal 
models and humans (Saide et al., 2019; Verstraelen et al., 2016; Vliegenthart 
et al., 2014). 
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3. For 1 biological replicate (n=1), use up to 10 embryos per drug concentration. 
Consequently 5 biological replicates (n=5) use a total of 50 embryos. 
1 biological replicate is defined as the embryos from one female. 
4. Seal plates with Breathe-EazyR sealing membranes to prevent evaporation, but 
allow exchange of gases.  
5. Incubate embryos from stage 38 to stage 45 at 23oC. This takes approximately 
2-3 days.  
Stage 38 corresponds to late organogenesis when the heart, vascular system, and 
other organs such as the liver are well developed. Between stages 38-45 the 
mouth opens and the gills and gut start to function.  
6. Proceed to Step 7 to measure differences in gene expression due to drug 
treatment, or Step 14 to measure changes in free glutathione due to drug 
treatment. 
Expression of miR-122 in different tissues of embryos 
7. Following drug treatment until stage 45, place the embryos into a clean petri 
dish of tricaine (0.5 mg/mL in 0.1X MMR) and incubate at 23°C for 1 h. Transfer 
to a petri dish coated with 2% agarose and dissect the embryos into tail and gut 
tissue using a simple razor as shown in Fig 1.  
Following this step, samples can be stored at -80oC. Place the samples in a 1.5-mL 
microfuge tube, remove all fluid, and snap freeze in liquid nitrogen for at least 2 min. 
We usually freeze 10 embryos per 1.5mL microfuge tube.  
The gut section contains the liver. The tail section does not contain any part of the liver 
and so liver markers observed are assumed to be in the extensive vasculature of the 
tail.  
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8. Pool the guts and tails separately for 10 embryos. Using a commercial kit, 
isolate the RNA and synthesize cDNA. We routinely use around 10 ng of RNA 
for cDNA synthesis. 
qRT-PCR 
9. Dilute the cDNA 1:80 in RNAse-free water.  
We empirically determined that this was the optimum dilution factor.  
10. Prepare reactions in a MicroAmp optical 96 well plate. Add 5 μL of the diluted 
cDNA, 0.5 μL of miRCURYTM LNA PCR Primer mix for Xenopus miR-122 
(Exiqon), 7.5 μL of 2x SYBR® Green PCR Master Mix (Applied Biosystems) 
and 2 μL of RNase free water for a final volume of 15 μL. 
11. Carry out PCR using an Applied Biosystems 7500 Fast Real-Time PCR system under 
the following conditions: 95°C for 10 min, 40 cycles at 95°C for 10 s and 60°C for 1 
min. 
We used miR-103 as a quantitative control for miR-122 expression of treated 
embryos using 0.5 μL of miRCURYTM LNA PCR Primer mix for Xenopus miR-103 
(Exiqon) 
Samples derived from embryos produced from different mothers are biological 
replicates. We test biological replicates were three times (technical replicates).  
qRT-PCR statistical analysis 
12.  Analyze gene expression using the Livak method (Livak and Schmittgen, 
2001). Take an average Ct value from the technical replicates and normalize 
that value to the Ct value for miR-103 expression and also to the untreated 
samples (embryos that received no drug treatment).  
13. Determine the fold change in gene expression using the formula: 2-ΔΔCT and 
convert this number into a logarithmic (log10). Perform Mann-Whitney tests 
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between gut and tail tissues from embryos treated with the same concentration 
of drug to determine statistical significance. 
Measuring free glutathione (GSH) 
Many compounds are metabolized in the liver to facilitate their excretion. In many 
cases including paracetamol this involves the metabolic addition of glutathione to a 
molecule. Here we provide a method to measure the depletion of free GSH in 
response to a drug.  
14. At the end of the incubation period described in Step 5, transfer 10 embryos 
that were treated with the same conditions into 1 microcentrifuge tube. Place 
the tube on ice.  
15. Remove as much of the incubation solution as possible. Add 125 L of 10 mM 
HCl. 
16. Homogenize embryos using an Eppendorf pestle and vortexing. 
17. Centrifuge at 14000g for 5 min at 4oC. 
18. Transfer 25 L of the supernatant to another tube and store at -80oC for protein 
quantification using a Bradford assay. Replace the 25 L with 25 L of 6.5 % 
(w/v) 5-sulfosalycylic acid hydrate (SSA). 
19. Remove all of the supernatant including the SSA and flash freeze in liquid 
Nitrogen. Store at -80oC until ready to perform the GSH assay. 
GSH Assay 
20. Prepare the following standard GSH concentrations: 0, 1, 2, 5, 10, 20, 30 and 
40 nmol/mL using GSH buffer and 0.1 mM GSH. Keep on ice. 
21. Mix 20 L of the standard or sample with 200 L GSH assay reagent in 1 well 
of a 96-well plate and incubate for 5 min at room temperature. 
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22. To each well add 50 L of 13 U/mL GSH reductase and gently shake before 
placing on the plate reader.  
23. Immediately measure the absorption of the plate at 405 nm using a 
spectrophotometer. 
24. Take 11 readings at 15s intervals.  
25. Use the reading with the best standard curve to calculate the sample results 
(nmol/mL).  
Bradford assay  
26. Prepare standard concentrations of BSA dissolved in 10 mM HCl: 0, 0.1, 0.2, 
0.4, 0.8, 1.2, 1.6, 2 and 4 mg/mL.  
27. Perform the assay according to the manufacturer’s instructions as follows.  
28. Add 5 μL of each sample from Step 18 to 1 well of a 96-well plate with 25 μL of 
reagent A + S (1 mL reagent A + 20 μL reagent S) and 200 μL of reagent B.  
29. Incubate for 15 min at room temperature. 
30.  Read the plate absorption at 595 nm absorption using a spectrophotometer. 
31. Divide the GSH results (nmol/mL) by the Bradford result (mg/mL) for each 
sample to give the final result (nmol/mg). 
 
DISCUSSION  
Predicting drug-induced toxicity is a big problem for Pharma in the 21st century. X. 
laevis embryos could be an ideal model organism to be used for screening new drugs 
and compounds as screening in Xenopus is comparatively high-throughput relative to 
screening in rodents (Tomlinson et al., 2009). We have previously developed methods 
to both screen compounds for novel phenotypes and test toxicity (Al-Yousuf et al., 
2017; Tomlinson et al., 2012; Tomlinson et al., 2009; Webster et al., 2016; Wheeler 
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and Liu, 2012, Saide et al., 2019). In addition, Xenopus embryos have been used as 
a toxicity model for drugs in their early stages of drug safety evaluation in the frog 
teratogenesis assay-Xenopus (or FETAX assay) (Leconte and Mouche, 2013). 
Xenopus embryos could assist in vitro drug-induced toxicity safety assessment in the 
early phases of drug development before moving on to expensive preclinical trials in 
mammals (Fig 2). The procedures outlined here can provide an assessment of the 
potential for a novel compound to cause hepatotoxicity in the tadpole model. Previous 
work in Xenopus suggests this could be translatable to the incidence of toxicity in 
higher vertebrates such as mice and humans (Saide et al., 2019). Many drugs such 
as paracetamol are metabolized in the liver and it is the metabolites that are often 
toxic. Preliminary work has shown that using mass spectroscopy of tadpole tissue to 
identify drug metabolites, such as those generated from paracetamol, is feasible (G. 
N. Wheeler, unpublished observation).  
The tail/vascular assay described here is also amenable to protein assays such as 
ELISAs. Known biomarkers that are released into the blood in hepatotoxic situations 
that could be tested in this way include alanine aminotransferase, aspartate 
aminotransferase, alkaline phosphatase, glutamate dehydrogenase, cytochrome C 
and keratin 18.  
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Figures: 
 
 
 
 
 
 
 
 
Figure 1: Drug development with Xenopus laevis 
The proposed use of Xenopus laevis embryos in assessing hepatoxicity would be in the early 
preclinical phase for the prediction of drug-induced toxicity. Xenopus embryos could bridge 
the gap between in vitro and in vivo safety studies. 
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Figure 2: Dissection for qRT-PCR miR-122 detection 
After drug exposure, stage 45 Xenopus embryos were anaesthetised and dissected along the 
lines indicated here (black arrows) to obtain gut (purple arrow) and tail (red arrow) regions. 
These regions are then processed to detect miR-122 expression by qRT-PCR. (Figure taken 
from Saide et al 2019) 
 
 
 
 
 
 
 
 
 
